Lyon, France, May 10, 2022 – 6:05 p.m. CET – MaaT Pharma (EURONEXT: MAAT – the “Company”), a late-stage French biotechnology company, a pioneer in the development of drugs for the restoration of the intestinal microbiota to improve the survival of cancer patients, announces, as part of its combined annual general meeting of May 31, 2022, the availability on its website of the documents referred to in Article R.22-10-23 of the French Commercial Code. The documents are available on the investor area of the Company’s website: www.maatpharma.com
For any additional information, you can send an e-mail to [email protected].